Delivery Order SPE2DB20D3103-SPE2DB25FP9F8
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $5,987.47 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitive award, issued under firm fixed pricing, represents a child contract to AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of...
- The Defense Logistics Agency awarded a $17,619.85 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 23, 2025, with completion scheduled for July 24, 2025. This firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The work will be performed at AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency awarded a $6,356.88 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Dupixent 200 mg/1.14 ml pen injectors. This firm fixed-price delivery order, which is expected to be completed by July 24, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The contract was competitively awarded with no set-aside...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $5,128.38 for Dupixent 300 mg/2 ml pen injectors on July 30, 2025, with completion scheduled for July 31, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a $20,290.04 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 24, 2025, with completion scheduled for July 25, 2025. This is a firm fixed price, non-set-aside contract performed at AmerisourceBergen's Conshohocken, Pennsylvania location. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive global...
- The Defense Logistics Agency awarded a delivery order valued at $9,106.78 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on August 11, 2025, with an ultimate completion date of August 12, 2025. This is a firm fixed price, non-set-aside contract for pharmaceutical delivery to support federal medical procurement needs. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a delivery order valued at $20,876.59 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 14, 2025, with an ultimate completion date of August 15, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitively awarded contract supporting the federal government's pharmaceutical supply chain. The contract will be performed at AmerisourceBergen's corporate office location...
- The Defense Logistics Agency awarded a delivery order valued at $21,925.15 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on July 30, 2025, with an ultimate completion date of July 31, 2025. This firm fixed-price delivery order is non-competitive and carries no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform this delivery from its corporate office location. The award represents a child order under...
- The Defense Logistics Agency awarded a delivery order valued at $36,944.08 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on August 14, 2025, with completion scheduled for August 15, 2025. This firm fixed price, competitively awarded delivery order represents a direct fulfillment under the company's existing pharmaceutical supply agreement with DLA. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors with a firm fixed price ceiling value of $12,041.74. This competitively awarded, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The pharmaceutical distributor, headquartered in...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FP9F8Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $20,568.10 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 18, 2025, with completion targeted for August 19, 2025. This is a firm fixed price, non-set-aside contract for pharmaceutical delivery to support federal medical procurement needs. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for military and veteran healthcare systems through the DLA Medical Supply Chain. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. The IDC enables the company to supply a comprehensive range of pharmaceutical products and medical supplies supporting military healthcare programs worldwide, including specialty medications, brand-name and generic drugs, and specialized medical commodities. Dupixent, a biologic medication used for conditions such as eczema and asthma, represents a specialized pharmaceutical commodity within the scope of this prime vendor arrangement serving the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $20.6k | 8/18/25 |